News | April 28, 2026
Aurigene bets big on CRDMO expansion with $100 million outlay
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Bolli will lead worldwide business development for the company’s Contract Development and Manufacturing Organisation (CDMO) services
Bidding window open till May 15; study to map costs and bottlenecks across pharma supply chains
Exclusive distribution pact with Amcor broadens access to Parafilm M sealing solutions for laboratories, horticulture and industrial users
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
Subscribe To Our Newsletter & Stay Updated
